Threshold Pharmaceuticals, Inc. Provides Update on Continued Promising Data From a Phase 1/2 Clinical Trial of TH-302 at the American Society of Clinical Oncology Annual Meeting

REDWOOD CITY, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold’s clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the American Society of Clinical Oncology Annual Meeting in Chicago.